Sign In To Continue
You have reached the guest article limit.
Unlock more of the IIPLA newsroom by signing in with SSO or joining as a member.
A US federal court has ruled that Biogen must pay Genentech $88 million in a patent royalty dispute concerning a multiple sclerosis drug. The judgment resolves a high-stakes conflict between two biotech giants over licensing agreements and revenue sharing tied to the drug's commercial success.
Share This Article
Ready-to-post copy includes the article link.
US Court Orders Biogen to Pay Genentech $88 Million in Multiple Sclerosis Drug Royalty Dispute A US federal court has ruled that Biogen must pay Genentech $88 million in a patent royalty dispute concerning a multiple sclerosis drug. The judgment resolves a high-stakes conflict between two biotech giants over lice... Read the full IIPLA article: https://iipla.org/news/us-court-orders-biogen-to-pay-genentech-88-million-in-multiple-sclerosis-drug-royalty-dispute